Johnson & Johnson To Push Diabetes Management Model
This article was originally published in PharmAsia News
Executive Summary
At the one-year anniversary of the establishment of the Beijing Diabetes Institute (PharmAsia News, Aug. 18, 2008), Johnson & Johnson announced that it will push to improve the prevention and treatment effectiveness of diabetes and its complications. Starting with Shanghai, Zhejiang, Liaoning, Heilongjiang and Chongqing, the project will set up a highly efficient and seamless diabetes management model between hospitals and the community. Since its establishment, the Beijing diabetes institute has conducted four sessions of diabetes educator training courses in China, teaching 173 students from 25 provinces. In line with the country's healthcare reform, the institution this year began to focus on promoting its diabetes management model, which targets early detection and standardized management of the disease. (Click here for more - Chinese language)
You may also be interested in...
Johnson & Johnson Establishes Beijing Diabetes Institute
Johnson & Johnson has established its diabetes institute in Beijing, one of the company's first batch of four non-commercial institutes worldwide. The facility provides a free training platform for China's diabetes educators and managers. Over the next three years, the institute will work with the Ministry of Health to bring together local and overseas specialists and academics in the field to explore new standardized models with Chinese characteristics for managing the disease. Analysts believe the diabetes management model will allow China to maximize its health care resources to derive the most social benefits, especially previously idle community resources. (Click here for more - Chinese Language)
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.